India, April 25 -- Lupin Digital Health, India's first evidence-based cardiology Digital Therapeutics (DTx) platform, has announced that its Lyfe platform has received approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO). This milestone marks a groundbreaking advancement in post-discharge integrated care, highlighting the potential of evidence-based digital therapeutics solutions to transform patient care.

Having undergone a rigorous application, review, and on-site audit process, this Class C Medical Device license reaffirms the platform's effectiveness and emphasizes its commitment to quality, safety, and rigour.

Lyfe is now India's first clinically proven remote cardiac rehabilitation prog...